

PG4114

**FAXED**

03/08/02

1:40P

A12

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: GARRILL, Karl Andrew, et. al.

Serial No.: 09/599,274 Group Art Unit: 3728

Filed: June 22, 2000 Examiner: J. Foster

For: Method and Package For Storing a Pressurized Container Containing a Drug

Commissioner for Patents  
Washington, D.C. 20231

FAX RECEIVED

MAR - 8 2002

PETITIONS OFFICE

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed

Copies of the references were submitted in parent application. Serial No. \_\_\_\_\_ (37 CFR 1.98(d))

Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

A.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B.  The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

Express Mail Label No.  
EV022190615US

FOAEL

03/08/02

1-40P

PG4114

C.  The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

Please charge required fees to Deposit Account No.07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,



Christopher P. Rogers  
Registration No. 36,334

8 March 2002  
Date:

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Telephone: (919) 483-1240  
Facsimile: (919) 483-7988